CommercialCoverageMedium impact
08.01.73i, Filgrastim (Neupogen®) and Related Biosimilars, and tbo-filgrastim (Granix®)
Independence Blue Cross·Oncology, Hematology, Internal Medicine +1 more·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
IBX updated their medical necessity criteria and coding requirements for Filgrastim (Neupogen®), related biosimilars, and tbo-filgrastim (Granix®). This pharmacy policy change affects billing and coverage determination for these white blood cell growth factors commonly used in oncology and hematology.
Action Required
By July 1, 2025: Billing team must review and update medical necessity documentation requirements for Filgrastim (Neupogen®), biosimilars, and tbo-filgrastim (Granix®) claims. Access the full policy at the IBX website to understand new coding and prior authorization requirements. Update billing system rules and provider documentation templates accordingly.